At the last check on Monday, Qiagen N.V.’s (NYSE:QGEN) stock was down -$1.01, moving down -2.17 percent to $45.62. The average number of shares traded per day over the past five days has been 1,274,920 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.50 fall in that time frame. In the last twenty days, the average volume was 1,120,025, while in the previous 50 days, it was 1,125,172.
Since last month, QGEN stock rose 1.81%. Shares of the company fell to $44.51 on 07/07/23, the lowest level in the past month. A 52-week high of $51.18 was reached on 01/12/23 after having rallying from a 52-week low of $40.38. Since the beginning of this year, QGEN’s stock price has dropped by -8.52% or -$4.25, and marked a new high 4 times. However, the stock has declined by -10.86% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, Qiagen N.V. (QGEN) has a P/E ratio of about 29.76. The stock’s beta is 0.36. Besides these, the trailing price-to-sales (P/S) ratio of 5.16, the price-to-book (PB) ratio of 2.92, and the price-to-cash flow ratio of 23.95 may also be considered.
Financial Health
In the three months ended March 30, Qiagen N.V.’s quick ratio stood at 2.10, while its current ratio was 2.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.42, and the total debt-to-equity ratio was 0.53. On the profitability front, the trailing twelve-month gross margin is 63.90% percent. In the year ended March 30, EBITDA margin amounted to 36.64%, whereas operating margins totaled 21.10%. Based on annual data, QGEN earned $1.38 billion in gross profit and brought in $2.14 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 8.30%. Return on equity (ROE) for the past 12 months was 10.40%.
In Qiagen N.V.’s quarter-end financial report for March 30, it reported total debt of $1.47 billion against cash and short-term investments of $687.6 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. QGEN’s revenue fell -43.46% during the quarter, while net income inched up to $2.08 billion. While analysts expected Qiagen N.V. to report $0.47 quarterly earnings, the actual figure was $0.51 per share, beating the consensus estimate by 8.50%. During the quarter, the company generated $157.31 million in EBITDA. The liabilities of Qiagen N.V. were 2.72 billion at the end of its most recent quarter ended March 30, and its total debt was $1.92 billion.
Technical Picture
This quick technical analysis looks at Qiagen N.V.’s (QGEN) price momentum. With a historical volatility rate of 14.10%, the RSI 9-day stood at 37.09% on 04 August.
With respect to its five-day moving average, the current Qiagen N.V. price is down by -3.18% percent or -$1.50. At present, QGEN shares trade +2.26% above its 20-day simple moving average and -1.72% percent below its 100-day simple moving average. However, the stock is currently trading approximately -0.67% below its SMA50 and +2.22% above its SMA200.
Stochastic coefficient K was 43.31% and Stochastic coefficient D was 54.33%, while ATR was 0.69. Given the Stochastic reading of 15.45% for the 14-day period, the RSI (14) reading has been calculated as 44.03%. As of today, the MACD Oscillator reading stands at -0.38, while the 14-day reading stands at -0.17.
Analyst Ratings
Morgan Stanley upgraded its rating on Qiagen N.V. (NYSE: QGEN) to an Overweight in a note to investors on May 23, 2023. The analysts firm previously had an Equal-weight rating on the stock.Qiagen N.V. (QGEN) has been rated Overweight by analysts. According to 0 brokerage firms, QGEN is a sell, and 11 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Qiagen N.V. stock as buy, with 8 recommending it as overweight.
With a median target price of $54.66, the current consensus forecast for the stock is $42.00 – $62.07. Based on these forecasts, analysts predict Qiagen N.V. (QGEN) will achieve an average price target of $53.54.
